Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 397-399

  Witzig, Thomas E ^a   Price Troska, Tammy L ^a   Stenson, Mary J ^a   Gupta, Mamta ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; JANUS KINASE 2; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PHENYLALANINE; RUXOLITINIB; SUPPRESSOR OF CYTOKINE SIGNALING; VALINE;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; CODON; EXON; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LETTER; MANTLE CELL LYMPHOMA; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LEUKEMIA; UNSPECIFIED SIDE EFFECT;

AMINO ACID SEQUENCE; BASE SEQUENCE; ENZYME ACTIVATION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ALIGNMENT;

EID: 84872045419     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.708931     Document Type: Letter

References (18)

1. Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515-1523.
2. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-3713.
3. Gupta M, Maurer M, Wellik L. STAT3 tyrosine phosphorylation is frequent in diffuse large Bcell lymphoma and is independent of molecular subtype: Implications for biomarker. Proceedings of the 103 rd Annual meeting of the AACR: 2012 Mar 31-Apr 4; Chicago, IL; Cancer Res 2012; 72.
4. Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: amechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-2853.
5. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
6. Libra M, Malaponte G, Navolanic PM, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005; 4: 1382-1384.
7. James C, Ugo V, Le Couedic JP, et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
9. Steensma DP, McClure RF, Karp JE, et al. JAK2 V617F is arare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971-978.
10. Levine RL, Loriaux M, Huntly BJ, et al. TheJAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
11. Melzner I, Weniger MA, Menz CK, et al. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006; 20: 157-158.
12. Chim CS, Wong KY, Loong F, et al. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 2004; 18: 356-358.
13. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-770.
14. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
15. Elliott NE, Cleveland SM, Grann V, et al. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911-3921.
16. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
17. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, aJAK1 and JAK2 inhibitor, in myelofibrosis. NEngl JMed 2010; 363: 1117-1127.
18. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, aselective JAK2 inhibitor, in myelofibrosis. JClin Oncol 2011; 29: 789-796.